Actively Recruiting
Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy
Led by Erasmus Medical Center · Updated on 2025-08-12
137
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
Sponsors
E
Erasmus Medical Center
Lead Sponsor
C
Cyted Health Inc
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.
CONDITIONS
Official Title
Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years and above with ultralong-segment Barrett's esophagus and clinically fit for endoscopy
- Ability to provide informed consent
You will not qualify if you...
- Diagnosis of oro-pharynx, esophageal, or gastro-esophageal tumor at T2 stage or above, or symptoms of dysphagia
- Presence of esophageal varices or strictures requiring esophageal dilation
- Cerebrovascular event within the past 6 months affecting swallowing
- Previous treatments for dysplastic Barrett's esophagus including Photodynamic Therapy, Radiofrequency Ablation, or Argon Plasma Coagulation
- Unable to provide informed consent
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Erasmus Medisch Centrum
Rotterdam, South Holland, Netherlands, 1315 GD
Actively Recruiting
Research Team
A
Anne-Elise C de Groen, MSc
CONTACT
J
Judith Honing, MSc, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here